Connect with us

Hi, what are you looking for?

Jewish Business News


Israel’s MediWound signs $112 million deal in U.S. for burn treatment

Israel's MediWound signs $112 million deal in U.S. for burn treatment


Clal Biotechnology Industries Ltd. reported to the Tel Aviv Stock Exchange Today that its wound and burn care solutions unit MediWound Ltd. has been awarded a $112 million contract by the US Biomedical Advanced Research & Development Authority (BARDA).

Investment group Clal Biotechnology, which has a 45 percent stake in MediWound, said that the five-year deal is for NexoBrid, which removes dead tissues from medium to severe burns, and will be used by the US authorities following incidents with many injured.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.


The U.S. body would also help MediWound get approval for its drug NexoBrid, a topical treatment that removes damaged tissue, from the Food and Drug Administration, Clal said in a statement.

The deal includes a $24 million payment by BARDA towards the development required in order to win US Food and Drug Administration (FDA) approval for NexoBrid.

In addition, BARDA is committing to buying $16 million worth of NextoBrid subject to FDA approval and using it in emergency situations (Emergency Use Authorization). The deal also includes an option for $22 million in financing expanded use of NexoBrid in other approved indications, and up to $50 million in additional purchases of the burns treatment.

BARDA, within the Office of the Assistant Secretary for Preparedness and Response in the US Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.

The Emergency Use Authorization (EUA) authority allows FDA to help strengthen the nation’s public health protections against CBRN threats by facilitating the availability and use of MCMs needed during public health emergencies.

Following this US federal funding, some of the $70 million raised on Nasdaq by MediWound in March 2014, can now be used for the development of other products.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.